Ribonucleic acid, or RNA, has emerged as a hot new field after mRNA and miRNA discoveries won Nobel Prizes in 2023 and 2024, respectively, drawing attention to its scientific value and industrial potential. In the medical field, RNA-based small nucleic acid drugs, by virtue of their broad target selection scope, higher clinical success rates, and durable effects, are poised to become leaders driving a third wave of highly targeted new drugs, following small-molecule drugs and antibody therapeutics. Against that backdrop, international investors will soon have a chance to buy into China's leading company within the small nucleic acid drugs sector.
Suzhou Ribo Life Science Co. Ltd., with 18 years of experience in small nucleic acid drugs, is launching its IPO in Hong Kong, positioning itself as a world leading player focused on small interfering RNA therapeutics, or siRNA.
After passing its listing hearing last month, the company officially launched its Hong Kong IPO on Dec. 31, aiming to raise about HK$1.59 billion ($205 million) by selling 27.5 million shares for HK$57.97 each. Heavyweight underwriters CICC and Citigroup are joint sponsors, signaling strong interest from both domestic Chinese and international investors.